share_log

Goldman Sachs Initiates Coverage On Rocket Pharmaceuticals With Neutral Rating, Announces Price Target of $39

Goldman Sachs Initiates Coverage On Rocket Pharmaceuticals With Neutral Rating, Announces Price Target of $39

高盛以中性評級啓動對火箭製藥的報道,宣佈目標股價爲39美元
Moomoo 24/7 ·  04/02 07:07

Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and announces Price Target of $39.

高盛分析師理查德·勞以中性評級啓動了對火箭製藥公司(納斯達克股票代碼:RCKT)的報道,並宣佈目標股價爲39美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論